Rapid Micro Biosystems Sees Growth with Big Pharma Adoption

Rapid Micro Biosystems has reported Q4 '25 and FY25 results, with growth driven by the adoption of its Growth Direct Platform by Big Pharma companies. The platform is used for microbiological testing in pharmaceutical manufacturing and research. While the results are small, the trend is positive, driven by the increasing demand for microbiological testing in the pharmaceutical industry.